WT1 Peptide-Pulsed Dendritic Cells: Clinical Trials

1 trial of WT1 Peptide-Pulsed Dendritic Cells, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Completed 1
Phase 21Completed 1

Follow WT1 Peptide-Pulsed Dendritic Cells: new trials by email Literature Review of WT1 Peptide-Pulsed Dendritic Cells trials Research Report on WT1 Peptide-Pulsed Dendritic Cells

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4 - Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL)
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)102008-02-222017-04-12

Conditions studied

Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Leukemia (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Myelodysplastic Syndromes (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Sponsors

National Cancer Institute (NCI) (1)

Countries

United States (1)

Top investigators

Terry J Fry, M.D. (1)